News
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: ...
Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 ...
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
1d
Stocktwits on MSNThis Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees OpportunityWells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
As Laura Loomer wields a terrifying amount of power, other far-right influencers are accusing her of being a “plant.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results